argenx announces results of Annual General Meeting of Shareholders
03 Mai 2023 - 10:01PM
GlobeNewswire Inc.
May 3,
2023
Amsterdam, the
Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, announced the
results of its Annual General Meeting of shareholders held
yesterday.
All items on the agenda received a majority of
votes in favor except for agenda item 3 (advisory non-binding vote
on the 2022 remuneration report).
As part of the approved resolutions:
- The Company's annual report and
annual accounts for the financial year ending December 31, 2022
were approved;
- Don deBethizy has been re-appointed
as non-executive director to the Board of Directors for a term of 2
years;
- The Board of Directors was
authorized to issue shares and grant rights to subscribe for shares
in the share capital of the company for up to 10% of the
outstanding share capital at the date of the meeting and for a
period of 18 months from the meeting; and
- Deloitte Accountants B.V. has been
appointed as the Company's auditor for the 2023 financial
year.
The voting result and all documents relating to
the shareholders’ meeting will be available on the argenx website
at www.argenx.com/investors/shareholder-meetings.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first-and- only
approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU
and UK, and Japan. The Company is evaluating efgartigimod in
multiple serious autoimmune diseases and advancing several earlier
stage experimental medicines within its therapeutic franchises. For
more information, visit https://www.argenx.com/ and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please
contact:
Media:Erin
Murphyemurphy@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
Lynn Eltonlelton@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Août 2023 à Sept 2023
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Sept 2022 à Sept 2023
